This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Gastric Adenocarcinoma
and you are
over 18
years old
-
The phase for this study is not defined.
Show me locations

The purpose

Trastuzumab plus chemotherapy is an effective therapy in HER2 positive advanced gastric cancer (AGC). However, the efficacy of routine trastuzumab therapy and its association with clinicopathologic factors remain unclear. The object of the study is to determine whether the addition of trastuzumab to first-line chemotherapy improves efficacy compared with chemotherapy alone in HER2 positive AGC.

Provided treatments

  • Drug: H+CT
Tris trial is registered with FDA with number: NCT03024450. The sponsor of the trial is Shanghai Zhongshan Hospital and it is looking for 98 volunteers for the current phase.
Official trial title:
Efficacy and Prognostic Factors of Trastuzumab Based Therapy in HER2 Positive Advanced Gastric Cancer: a Single Center Prospective Observational Study